关注
Islam Eljilany
Islam Eljilany
Cancer Researcher at H. Lee Moffitt Cancer Center and Research Institute
在 Moffitt.org 的电子邮件经过验证
标题
引用次数
引用次数
年份
D-dimer, fibrinogen, and IL-6 in COVID-19 patients with suspected venous thromboembolism: a narrative review
I Eljilany, AN Elzouki
Vascular health and risk management, 455-462, 2020
1752020
Evaluating quantity and quality of literature focusing on health economics and pharmacoeconomics in Gulf Cooperation Council countries
I Eljilany, F El-Dahiyat, LE Curley, ZUD Babar
Expert Review of Pharmacoeconomics & Outcomes Research 18 (4), 403-414, 2018
192018
Warfarin dosing strategies evolution and its progress in the era of precision medicine, a narrative review
AM Fahmi, H Elewa, I El Jilany
International Journal of Clinical Pharmacy 44 (3), 599-607, 2022
172022
Granulomatous and sarcoid-like immune-related adverse events following CTLA4 and PD1 blockade adjuvant therapy of melanoma: a combined analysis of ECOG-ACRIN E1609 and SWOG …
I Eljilany, A Noor, M Paravathaneni, I Yassine, SJ Lee, M Othus, J Moon, ...
Cancers 15 (9), 2561, 2023
82023
Genetic polymorphism effect on warfarin–rifampin Interaction: a case report and review of literature
M Salem, I Eljilany, A El-Bardissy, H Elewa
Pharmacogenomics and Personalized Medicine, 149-156, 2021
82021
Cost-minimization analysis of ranibizumab versus aflibercept for treating Saudi patients with visual impairment owing to age-related macular degeneration or diabetic macular edema
F El-Dahiyat, I Eljilany
Value in Health Regional Issues 22, 23-26, 2020
82020
Adjuvant therapy for high-risk melanoma: An in-depth examination of the state of the field
I Eljilany, E Castellano, AA Tarhini
Cancers 15 (16), 4125, 2023
62023
Cost-benefit analysis of genotype-guided interruption days in warfarin pre-procedural management
I Eljilany, H Elewa, D Al-Badriyeh
Current problems in cardiology 48 (6), 101128, 2023
62023
Assessment of the attitude, awareness and practice of periprocedural warfarin management among health care professional in Qatar. A cross sectional survey
I Eljilany, A El-Bardissy, A Nemir, AN Elzouki, I El Madhoun, ...
Journal of Thrombosis and Thrombolysis 50 (4), 957-968, 2020
62020
Genetic and non-genetic factors impact on INR normalization in preprocedural warfarin management
I Eljilany, M Elarref, N Shallik, AN Elzouki, L Bader, A El-Bardissy, ...
Pharmacogenomics and Personalized Medicine, 1069-1080, 2021
52021
The T Cell Immunoscore as a Reference for Biomarker Development Utilizing Real-World Data from Patients with Advanced Malignancies Treated with Immune Checkpoint Inhibitors
I Eljilany, PG Saghand, J Chen, A Ratan, M McCarter, J Carpten, ...
Cancers 15 (20), 4913, 2023
42023
A tumor and immune-related micro-RNA signature predicts relapse-free survival of melanoma patients treated with Ipilimumab
I Kobeissi, I Eljilany, T Achkar, WA LaFramboise, L Santana-Santos, ...
International journal of molecular sciences 24 (9), 8167, 2023
42023
Periprocedural anticoagulation management of patients receiving warfarin in qatar: a prospective cohort study
I Eljilany, M Elarref, N Shallik, AN Elzouki, AM Mohammed, B Shoman, ...
Current Problems in Cardiology 46 (6), 100816, 2021
42021
The tumor microbiome as a predictor of outcomes in patients with metastatic melanoma treated with immune checkpoint inhibitors
CE Wheeler, SS Coleman IV, R Hoyd, L Denko, CHF Chan, ...
bioRxiv, 2023
32023
The tumor microbiome reacts to hypoxia and can influence response to radiation treatment in colorectal cancer
M Benej, R Hoyd, MK Kreamer, CE Wheeler, DJ Grencewicz, F Choueiry, ...
Cancer research communications 4 (7), 1690-1701, 2024
22024
Treatment of Stage III Resectable Melanoma—Adjuvant and Neoadjuvant Approaches
AA Tarhini, E Castellano, I Eljilany
The Cancer Journal 30 (2), 54-70, 2024
22024
A bioinformatics tool for identifying intratumoral microbes from the ORIEN dataset
C Wang, A Ma, Y Li, ME McNutt, S Zhang, J Zhu, R Hoyd, CE Wheeler, ...
Cancer research communications 4 (2), 293-302, 2024
22024
Bridging vs Non-Bridging with Warfarin Peri-Procedural Management: Cost and Cost-Effectiveness Analyses
I Eljilany, H Elewa, O Abdelsamad, M Abdelgelil, A Mahfouz, R Al Anany, ...
Current Problems in Cardiology 46 (11), 100839, 2021
22021
Assessing the Performance of In silico Tools and Molecular Dynamics Simulations for Predicting Pharmacogenetic Variant Impact
MJ AlSaeed, P Ramdhan, JG Malave, I Eljilany, T Langaee, ...
Clinical Pharmacology & Therapeutics 116 (4), 1082-1089, 2024
12024
The tumor microbiome as a predictor of outcomes in patients with metastatic melanoma treated with immune checkpoint inhibitors
CE Dravillas, SS Coleman IV, R Hoyd, G Caryotakis, L Denko, CHF Chan, ...
Cancer research communications 4 (8), 1978-1990, 2024
12024
系统目前无法执行此操作,请稍后再试。
文章 1–20